{"nctId":"NCT00536263","briefTitle":"PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327)","startDateStruct":{"date":"2007-09"},"conditions":["Hepatitis B, Chronic"],"count":671,"armGroups":[{"label":"PEG 1.0 mcg/kg weekly (QW) * 24 weeks","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: pegylated interferon alpha-2b"]},{"label":"PEG 1.5 mcg/kg QW * 24 wks","type":"EXPERIMENTAL","interventionNames":["Drug: pegylated interferon alpha-2b"]},{"label":"PEG 1.5 mcg/kg QW * 48 wks","type":"EXPERIMENTAL","interventionNames":["Drug: pegylated interferon alpha-2b"]}],"interventions":[{"name":"pegylated interferon alpha-2b","otherNames":[]},{"name":"pegylated interferon alpha-2b","otherNames":[]},{"name":"pegylated interferon alpha-2b","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adults with chronic hepatitis B:\n\n  * Serum hepatitis B surface antigen positive for at least 6 months\n  * Serum hepatitis B e antigen positive\n  * Serum negative for hepatitis B surface and e antibodies\n  * Plasma hepatitis B virus deoxyribonucleic acid (DNA) level greater than 20,000 IU/mL\n  * Alanine aminotransferase (ALT) 2- to 10-times the upper limit of normal\n* Compensated liver disease with certain minimum hematological and serum biochemical criteria\n\nExclusion Criteria:\n\n* Significant hepatic disease from an etiology other than hepatitis B virus\n* Antiviral treatment for hepatitis within previous 6 months\n* History of severe psychiatric disease, especially depression\n* Unstable or significant cardiovascular disease\n* Prolonged exposure to known hepatotoxins such as alcohol or drugs\n* Any condition that could interfere with the subject participating in and completing the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Hepatitis B Envelope Antigen (HBe or HBeAg) Loss","description":"HBeAg Loss was tested by Abbott Microparticle Enzyme Immunoassay (MEIA)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"40","spread":null},{"groupId":"OG002","value":"70","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With HBeAg Loss","description":"HBeAg Loss was tested by assay of Abbott MEIA","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"28","spread":null},{"groupId":"OG002","value":"43","spread":null}]}]}]},{"type":"SECONDARY","title":"HBe Seroconversion","description":"HBe seroconversion was defined as HBeAg Loss and Anti-HBeAg Positive. These were tested by assay of Abbott MEIA.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"36","spread":null},{"groupId":"OG002","value":"67","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Hepatitis B Virus - Deoxyriboncleic Acid (HBV-DNA) <20,000 IU/mL","description":"HBV-DNA was tested by assay of Roche Cobas Taqman (the test\n\nlowest limit is 6 IU/mL)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"61","spread":null},{"groupId":"OG002","value":"76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"47","spread":null},{"groupId":"OG002","value":"75","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With HBV-DNA < 200 IU/mL","description":"HBV-DNA was tested by assay of Roche Cobas Taqman (the test lowest limit is 6 IU/mL)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"22","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With HBV-DNA Undetectable","description":"Undetectable HBV-DNA was defined as having a level \\<6 IU/mL by polymerase chain reaction (PCR).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Biochemical Response","description":"Biochemical response was defined as alanine aminotransferase (ALT) normalization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"86","spread":null},{"groupId":"OG002","value":"103","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"80","spread":null},{"groupId":"OG002","value":"103","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Combined Response","description":"Combined response was defined as HBV DNA \\<20,000 IU/mL and HBe seroconversion and alanine aminotransferase (ALT) normalization","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"45","spread":null}]}]}]},{"type":"SECONDARY","title":"Hepatitis B Surface Antigen (HBsAg) Loss","description":"HBsAg Loss was tested by assay of Abbott MEIA","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Hepatitis B Surface Antigen (HBs) Seroconversion","description":"HBs seroconversion was defined as having HBsAg Loss and Anti-HBs Positive","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Liver Biopsy Score","description":"Method for biopsy scoring was Knodell Scoring System (Histology Activity Index-HAI Score System):\n\nScore I (periportal +/- bridging necrosis): 0 (none) to 10 (multilobular necrosis).\n\nScore II (Intralobular degeneration and focal necrosis): 0 (none) to 4 (Marked \\[involvement of \\>2/3 of lobules or nodules\\]).\n\nScore III (portal inflammation): 0 (none) to 4 (Marked \\[dense packing of\n\ninflammatory cells in \\>2/3 of portal tracts\\]).\n\nScore IV (fibrosis): 0 (none) to 4 (cirrhosis).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":"3.06"},{"groupId":"OG001","value":"8.4","spread":"2.92"},{"groupId":"OG002","value":"8.2","spread":"3.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"3.57"},{"groupId":"OG001","value":"-1.7","spread":"3.66"},{"groupId":"OG002","value":"-1.6","spread":"3.96"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":225},"commonTop":["PYREXIA","MYALGIA","HEADACHE","FATIGUE","ALOPECIA"]}}}